Comparator: raltegravir

DRUG2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

HIV InfectionHuman Immunodeficiency Virus

Phase 3

MK0518 in the Treatment of HIV-Infected Patients Switched From a Protease Inhibitor Regimen (0518-033)(TERMINATED)

TerminatedNCT00443729

Merck Sharp & Dohme LLCHIV Infection

Start: 2007-05-31End: 2009-04-30Updated: 2017-03-21

A Study of Raltegravir in a Diverse Cohort of HIV-Infected Patients (0518-055)

CompletedNCT00764946

Merck Sharp & Dohme LLCHuman Immunodeficiency Virus

Start: 2008-10-31End: 2011-02-28Updated: 2017-03-21

Related Papers

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.

2010-01-12214 citations